drugset

drugset / Trial / NCT02211859

Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit

NCT02211859 ↗

Phase 1 Completed 70 enrolled Boehringer Ingelheim

NaSingle-groupOpen-labelTreatment

Summary

Primary: Maximum tolerated dose (MTD) Secondary: Determination of the pharmacokinetic profile of BI 2536. Assessment of safety and efficacy.

Timeline

Start: 2004-08
Primary completion: 2007-12
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BI 2536	Small molecule	—	Intravenous

Indications